Johnson & Johnson's ($JNJ) marketing is under the U.S. microscope again. As The Wall Street Journal reports, the feds issued a subpoena for information about J&J's Nucynta promotions, in the government's latest probe of potentially improper drug marketing.
Issued by the Department of Health and Human Services' inspector general, the subpoena is looking for documents and information about sales, marketing and promotional activities on two formulations of Nucynta, an opioid pain reliever. The subpoena specifically mentions payments to doctors, which usually means investigators are looking into potential kickbacks. And it asks for study data on Nucynta's safety, plus any reports or complaints of side effects, theWSJ notes.
A J&J spokeswoman told the Journal that the company is cooperating with the requests.